Literature DB >> 27077642

NGR Tumor-Homing Peptides: Structural Requirements for Effective APN (CD13) Targeting.

Alessandra Graziadio1, Matteo Zanda1,2, Simona Frau1, Ian N Fleming1, Manuele Musolino1, Sergio Dall'Angelo1, Massimiliano Baldassarre1, Monica Piras1.   

Abstract

Cyclic CNGRC (cCNGRC) peptides are very important targeting ligands for Aminopeptidase N (APN or CD13), which is overexpressed on the surface of many cancer cells. In this work we have (1) developed an efficient solid-phase synthesis and (2) tested on purified porcine APN and APN-expressing human cells two different classes of cCNGRC peptides: the first carrying a biotin affinity tag or a fluorescent tag attached to the carboxyl Arg-Cys-COOH terminus and the second with the tags attached to the amino H2N-Cys-Asn terminus. Carboxyl-terminus functionalized cCNGRC peptides 3, 6, and 8 showed good affinity for porcine APN and very good capacity to target and be internalized into APN-expressing cells. In contrast, amino-terminus functionalized cCNGRC peptides 4, 5, and 7 displayed significantly decreased affinity and targeting capacity. These results, which are in agreement with the recently reported X-ray structure of a cCNGRC peptide bound to APN showing important stabilizing interactions between the unprotected cCNGRC amino terminus and the APN active site, indicate that the carboxyl and not the amino-terminus of cCNGRC peptides should be used as a "handle" for the attachment of toxic payloads for therapy or isotopically labeled functions for imaging and nuclear medicine.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27077642     DOI: 10.1021/acs.bioconjchem.6b00136

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  7 in total

1.  NGR-peptide-drug conjugates with dual targeting properties.

Authors:  Kata Nóra Enyedi; Szilárd Tóth; Gergely Szakács; Gábor Mező
Journal:  PLoS One       Date:  2017-06-02       Impact factor: 3.240

Review 2.  Nanocomposites as biomolecules delivery agents in nanomedicine.

Authors:  Magdalena Bamburowicz-Klimkowska; Magdalena Poplawska; Ireneusz P Grudzinski
Journal:  J Nanobiotechnology       Date:  2019-04-03       Impact factor: 9.429

3.  In vitro studies on CNGRC-CPG2 fusion proteins for ligand-directed enzyme prodrug therapy for targeted cancer therapy.

Authors:  Layla Al-Mansoori; Sara S Bashraheel; Alanod D Al Qahtani; C David O'Connor; Philip Elsinga; Sayed K Goda
Journal:  Oncotarget       Date:  2020-02-11

4.  Peptide-based delivery vectors with pre-defined geometrical locks.

Authors:  Ruchika Goyal; Gaurav Jerath; Aneesh Chandrasekharan; T R Santhosh Kumar; Vibin Ramakrishnan
Journal:  RSC Med Chem       Date:  2020-08-13

Review 5.  Molecular Imaging of Aminopeptidase N in Cancer and Angiogenesis.

Authors:  Cynthia L Schreiber; Bradley D Smith
Journal:  Contrast Media Mol Imaging       Date:  2018-06-25       Impact factor: 3.161

6.  Deepened cellular/subcellular interface penetration and enhanced antitumor efficacy of cyclic peptidic ligand-decorated accelerating active targeted nanomedicines.

Authors:  Nian-Qiu Shi; Yan Li; Yong Zhang; Zheng-Qiang Li; Xian-Rong Qi
Journal:  Int J Nanomedicine       Date:  2018-09-19

7.  In Vivo Imaging of Hypoxia and Neoangiogenesis in Experimental Syngeneic Hepatocellular Carcinoma Tumor Model Using Positron Emission Tomography.

Authors:  Adrienn Kis; Judit P Szabó; Noémi Dénes; Adrienn Vágner; Gábor Nagy; Ildikó Garai; Anikó Fekete; Dezső Szikra; István Hajdu; Orsolya Matolay; Gábor Méhes; Gábor Mező; István Kertész; György Trencsényi
Journal:  Biomed Res Int       Date:  2020-08-07       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.